| LEADER |
03036nam a2200337 4500 |
| 001 |
1538515 |
| 041 |
|
|
|a eng
|
| 100 |
|
|
|9 647514
|a Al-Ramamneh, Rahmeh Saad
|e Author
|
| 245 |
|
|
|a ELT-2017 Inhibits Tumour Growth and Prevents Triple Negative Breast Cancer Invasion in Model Systems through Dysregulation of Ran-GTP
|
| 260 |
|
|
|a السلط
|c 2021
|
| 300 |
|
|
|a 1 - 71
|
| 336 |
|
|
|a رسائل جامعية
|
| 502 |
|
|
|b رسالة ماجستير
|c جامعة عمان الأهلية
|f عمادة الدراسات العليا والبحث العلمي
|g الاردن
|o 0124
|
| 520 |
|
|
|a Triple negative breast cancer is one of the most aggressive tumors with dismal survival and a high death rate due to lake of any target therapy. Overexpression of the RAN GTP (RAN) gene has been shown to be linked to metastatic activity of MDA-MB-231 human breast cancer cells. The aim of this study was to investigate the potential of MELT-2017 as anticancer, targeted against the RAN gene, and to assess their effects in a range of biological assays. Methods The anticancer activity of MELT-2017 examined on MDA-MB-231 breast cancer cell line and A549 lung cancer cell line, using the [3-(4,5-dimetiltiazol-2-il)-2,5-difenil tetrazolium bromide] MTT assay. Inhibition of the cell cycle and increased apoptosis were analysed by flowcytometry [propidium iodide (PI) and Annexin V staining], Also the anti-metastatic activity of MELT-2017 was investigated by using migration, invasion and colony formation assays. Finally, the expression levels of RAN GTP (RAN) gene were assessed using quantitative RT-PCR. Results MELT-2017 inhibited cell proliferation in MDA-MB-231 breast cancer cell line and A549 lung cancer cell line (IC50 10.6 μM for MDA-MB-231 and 25.3 μM for A549 cells), Annexin V assay verified that the cytotoxic effect of MELT-2017 was through apoptotic pathway on both cell lines. Furthermore, MELT-2017 also suppressed invasion and migration, and down regulated RAN GTPase in both cell line. Conclusion Current findings suggest that MELT-2017 may be potential therapeutic agents against TNBC.
|
| 653 |
|
|
|a العقاقير الطبية
|a الخلايا السرطانية
|a الاختبارات البيولوجية
|
| 700 |
|
|
|9 647516
|a Kandil, Yasser Ibrahim
|e Advisor
|
| 700 |
|
|
|a El-Tanani, Mohamed
|e Advisor
|9 625870
|
| 856 |
|
|
|u 9802-028-001-0124-T.pdf
|y صفحة العنوان
|
| 856 |
|
|
|u 9802-028-001-0124-A.pdf
|y المستخلص
|
| 856 |
|
|
|u 9802-028-001-0124-C.pdf
|y قائمة المحتويات
|
| 856 |
|
|
|u 9802-028-001-0124-F.pdf
|y 24 صفحة الأولى
|
| 856 |
|
|
|u 9802-028-001-0124-1.pdf
|y 1 الفصل
|
| 856 |
|
|
|u 9802-028-001-0124-2.pdf
|y 2 الفصل
|
| 856 |
|
|
|u 9802-028-001-0124-3.pdf
|y 3 الفصل
|
| 856 |
|
|
|u 9802-028-001-0124-4.pdf
|y 4 الفصل
|
| 856 |
|
|
|u 9802-028-001-0124-5.pdf
|y 5 الفصل
|
| 856 |
|
|
|u 9802-028-001-0124-O.pdf
|y الخاتمة
|
| 856 |
|
|
|u 9802-028-001-0124-R.pdf
|y المصادر والمراجع
|
| 930 |
|
|
|d y
|
| 995 |
|
|
|a Dissertations
|
| 999 |
|
|
|c 1210690
|d 1210690
|
